✦ LIBER ✦

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

✍ Scribed by Radny, P; Caroli, U M; Bauer, J; Paul, T; Schlegel, C; Eigentler, T K; Weide, B; Schwarz, M; Garbe, C

Book ID: 109997787
Publisher: Nature Publishing Group
Year: 2003
Tongue: English
Weight: 301 KB
Volume: 89
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6601320

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I/II study of topical imiquimod an

Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma

✍ D.S. Green; M.D. Bodman-Smith; A.G. Dalgleish; M.D. Fischer 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 275 KB

Experience in the Treatment of Cutaneous

Experience in the Treatment of Cutaneous In-Transit Melanoma Metastases and Satellitosis With Intralesional Interleukin-2

✍ L.A. Dehesa; J. Vilar-Alejo; P. Valerón-Almazán; G. Carretero 📂 Article 📅 2009 🏛 Elsevier Science 🌐 Spanish ⚖ 410 KB

Phase II trial of trimetrexate in patien

Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma

✍ Jonathan D. Licht; René Gonin; Karen H. Antman 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 241 KB

Biochemotherapy with low doses of subcut

Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial

✍ María González Cao; Susana Puig; Josep Malvehy; Josep Eugeni Herrero; Rosa María 📂 Article 📅 2005 🏛 Springer Milan 🌐 Spanish ⚖ 112 KB

Phase I trial of subcutaneous recombinan

Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma

✍ Omar Eton; Michael G. Rosenblum; Sewa S. Legha; Wehei Zhang; Mary Jo East; Agop 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 3 views

## Abstract ## BACKGROUND Interleukin‐2 (IL‐2) has activity in metastatic melanoma when given in high doses by the intravenous (IV) route, but its side effects and effectiveness when given in intermediate to high doses by the subcutaneous (SC) route have not been studied adequately. This study sou

A phase II trial of PALA+dipyridamole in

A phase II trial of PALA+dipyridamole in patients with advanced soft-tissue sarcoma

✍ Ephraim S. Casper; Jose Baselga; Tracy B. Smart; Gordon B. Magill; Maurie Markma 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 455 KB